Our team combines deep technology and therapeutics expertise with strong operational and commercial experience.
Dr. Debora Lucarelli, Chief Executive Officer
Debora has a wealth of experience in technology development and a strong track record of successfully delivering large-scale projects in academia and industry. Previously, she led a cancer signature discovery program at Cambridge Epigenetix, directed laboratory research in large population studies (Head of laboratory, MRC Epidemiology, University of Cambridge) and worked on the development of the Oxford Nanopore’s technology. At Enhanc3D Genomics Debora is driving development of the technical platforms, establishing partnerships across the pharma and biotech industry and advocating the advent of a 3D genomics era.
Peter Bream, Chief Financial Officer
Peter has over 30 years of experience in international business ranging from start-ups to blue-chip companies. He has previously been CFO of public companies listed on the LSE and NASDAQ, in a range of industries including pharmaceuticals, medical diagnostics, engineering and chemicals with market capitalisations ranging from $10 million to $2 billion. Peter is currently a Non-Executive Director and Chair of the audit committee for an AIM listed healthcare business.
Dr. Nic Walker, Chief Technology Officer
Nic has 20 years of experience extracting and developing tools for insight from complex datasets in biotech, research institutes, and start-ups. His domain expertise crosses epigenomics, molecular technology development, cancer diagnostics, software engineering and machine learning. Prior to joining Enhanc3D Genomics Nic conducted research at the University of Cambridge in Epigenomics and was the Director of Data Science at Cambridge Epigenetix Ltd.
Dr. Stefan Schoenfelder, Chief Scientific Officer
Stefan is a recognised expert in the area of 3D genome organisation and function. Having led the development of Capture Hi-C while working in Prof. Fraser’s laboratory, Stefan is a group leader in the Epigenetics Programme at the Babraham Institute. He co-founded Enhanc3D in 2020 and continues to serve as CSO.
Hazel Jones, Chief Operating Officer
Hazel has significant oncology research experience, both in pharma/biotech and academic/charity sectors. She has a focus on long term strategic planning, both of logistics and scientific deliverables, as well as driving operational change. Hazel brings with her a broad understanding of all stages of drug development. We look forward to Hazel joining the C-Suite, driving the growth of the company.